This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Eisbruch, A. Articles by Lawrence, T. S. Search for Related Content PubMed PubMed Citation Articles by Eisbruch, A. Articles by Lawrence, T. S. Social Bookmarking                            What's this?

Bromodeoxyuridine Alternating With Radiation for Advanced Uterine Cervix Cancer: A Phase I and Drug Incorporation Study

From the Departments of Radiation Oncology, Obstetrics-Gynecology, and Pathology, University of Michigan, Ann Arbor, MI.

Address reprint requests to Avraham Eisbruch, MD, Department of Radiation Oncology, University of Michigan Hospitals, Ann Arbor MI 48109; Email eisbruch{at}umich.edu

PURPOSE: Preclinical studies show a significant increase in the ratio of the radiosensitizer bromodeoxyuridine (BUdR) in tumors versus the intestinal mucosa during the drug elimination period, compared with the ratio during drug infusion. We constructed a phase I study in patients with locally advanced cervix cancer, using alternating cycles of BUdR and radiation therapy (RT).

PATIENTS AND METHODS: Eighteen patients with stage IIB to IVA cervix cancer participated. A treatment cycle consisted of a 4-day BUdR infusion followed by a week of pelvic RT, 15 Gy twice daily in 1.5-Gy fractions. After three cycles, additional BUdR was infused, followed by brachytherapy. The fraction of thymidine replaced by BUdR and the fraction of cells incorporating BUdR were determined in rectal mucosa and tumor biopsies at the end of the first BUdR infusion (day 5), at the middle of the first RT week (day 10), and at the time of brachytherapy.

RESULTS: Dose-limiting toxicity was observed in one of 16 patients receiving 1,000 mg/m²/d x 4 days and inboth patients receiving 1,333 mg/m²/d x 4 days each cycle. After a median follow-up of 39 months, 12 patients (66%) were free of pelvic disease and nine (50%) were alive and disease free. The ratio of tumor to rectum BUdR incorporation averaged 1.5 to 1.8 and did not differ significantly between day 5 and day 10. A trend toward reduced ratio was observed at brachytherapy. Drug-containing cells in rectal biopsies migrated from the crypts to the mucosal surface.

CONCLUSION: In this schedule, 1,000 mg/m²/d is the maximum-tolerated dose of BUdR. BUdR incorporation levels in tumors were consistent with clinically significant radiosensitization. The migration of BUdR-containing rectal mucosa cells from the crypts to the surface at the time of RT suggests that this regimen may offer a relative sparing of the mucosa from radiosensitization.

Presented in part at the 40th Annual Meeting of the American Society of Therapeutic Radiology and Oncology, Phoenix, AZ, October 1998.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. Seo, T. Yan, J. E. Schupp, T. Radivoyevitch, and T. J. Kinsella Schedule-Dependent Drug Effects of Oral 5-Iodo-2-Pyrimidinone-2'-Deoxyribose as an In vivo Radiosensitizer in U251 Human Glioblastoma Xenografts Clin. Cancer Res., October 15, 2005; 11(20): 7499 - 7507. [Abstract] [Full Text] [PDF]

				Y. Seo, T. Yan, J. E. Schupp, V. Colussi, K. L. Taylor, and T. J. Kinsella Differential Radiosensitization in DNA Mismatch Repair-Proficient and -Deficient Human Colon Cancer Xenografts with 5-Iodo-2-pyrimidinone-2'-deoxyribose Clin. Cancer Res., November 15, 2004; 10(22): 7520 - 7528. [Abstract] [Full Text] [PDF]

				L. B. Harrison, M. Chadha, R. J. Hill, K. Hu, and D. Shasha Impact of Tumor Hypoxia and Anemia on Radiation Therapy Outcomes Oncologist, December 1, 2002; 7(6): 492 - 508. [Abstract] [Full Text] [PDF]

				T. J. Kinsella, J. E. Schupp, T. W. Davis, S. E. Berry, H.-S. Hwang, K. Warren, F. Balis, J. Barnett, and H. Sands Preclinical Study of the Systemic Toxicity and Pharmacokinetics of 5-Iodo-2-deoxypyrimidinone-2'-deoxyribose as a Radiosensitizing Prodrug in Two, Non-Rodent Animal Species: Implications for Phase I Study Design Clin. Cancer Res., September 1, 2000; 6(9): 3670 - 3679. [Abstract] [Full Text]

				T. J. Kinsella, K. A. Vielhuber, K. A. Kunugi, J. Schupp, T. W. Davis, and H. Sands Preclinical Toxicity and Efficacy Study of a 14-day Schedule of Oral 5-Iodo-2-pyrimidinone-2'-deoxyribose as a Prodrug for 5-Iodo-2'-deoxyuridine Radiosensitization in U251 Human Glioblastoma Xenografts Clin. Cancer Res., April 1, 2000; 6(4): 1468 - 1475. [Abstract] [Full Text]

				C. N. Coleman and J. B. Mitchell Clinical Radiosensitization: Why It Does and Does Not Work J. Clin. Oncol., January 1, 1999; 17(1): 1 - 1. [Full Text] [PDF]